Evidence map›Paper›PMID 41200196›Full record

ArticleFrontiers in immunology2025

Case Report: Molecular and immunological insights into primary extramedullary plasmacytoma: discovery of a novel

Ziting Gao, Dongbing Li, Tingting Zhang, Wenfeng Su, Jintao Xu, Yuanjie Zhuang, Rong Cao, Yufei Xie, Xingping Lang, Huafei Chen and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ziting Gao *Department of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Dongbing Li *Molecular Genetics Laboratory, Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, Jiangsu, China.
Tingting Zhang *Department of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Wenfeng SuDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Jintao XuDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Yuanjie ZhuangDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Rong CaoDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Yufei XieMolecular Genetics Laboratory, Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, Jiangsu, China.
Xingping LangMolecular Genetics Laboratory, Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, Jiangsu, China.
Huafei ChenMolecular Genetics Laboratory, Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, Jiangsu, China.
Chunlin FanDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Xi YangDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Hongming HuangDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Dan GuoDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extramedullary Plasmacytoma (EMP) is a rare plasma cell neoplasm that originates outside the bone marrow. Primary Extramedullary Plasmacytoma with Diffuse Lymph Node Involvement (PLNEMP) is exceptionally rare. Here, we report a unique case of PLNEMP and significant bone destruction, characterized by a novel

Indexed as

Immunoglobulin Heavy ChainsNF-kappa B p50 SubunitOncogene Proteins, FusionPlasmacytomaAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionHumansMaleMiddle AgedImmunoglobulin Heavy ChainsNF-kappa B p50 SubunitNFKB1 protein, humanOncogene Proteins, Fusionbone destructionCAR-T therapychemotherapyextramedullary plasmacytomaIGH::NFKB1 fusionNF-κB pathway

Identifiers

PMID41200196
PMCPMC12585950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.